CGRP inhibitors
help treat and prevent migraine by impacting a protein that helps ignite a migraine attack.
Back
The protein, calcitonin gene-related peptide (CGRP), affects the trigeminal nerve, which communicates touch, temperature, and other sensations to parts of the face, eyes, and jaw.
Increased levels of CGRP in the blood can be a marker in chronic migraine diagnosis.
When the CGRP protein binds with the trigeminal nerve, it sets off the inflammation and pain that causes a migraine attack.
CGRP inhibitors stop this protein in one of two ways, either by either blocking the protein itself or blocking the receptor in the brain it binds to.
CGRP inhibitors can stay active in the body for quite some time, potentially preventing migraine attacks for weeks or even months.
CGRP inhibitors are the first drugs created specifically to treat migraine.
Replay
